US biotech Rigel Pharmaceutical’s (Nasdaq: RIGL) shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company
Rigal has entered into an exclusive license and supply agreement with Japan’s Kissei Pharmaceutical (TYO: 4547) to develop and commercialize Rezlidhia (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan.
Rezlidhia is commercially available to patients in the USA for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). Rigel has an existing agreement with Kisseito develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP) and in all other potential indications in Japan, China, Taiwan and the Republic of Korea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze